Literature DB >> 58523

Generalized pustular psoriasis. A report on thirteen patients.

S Lindgren, O Groth.   

Abstract

Generalized pustular psoriasis shows a fluctuating pattern, its course varying with time and from patient to patient. The prognosis and results of treatment are therefore extremely difficult to assess. The patients in this series have been followed up by us with regard to the natural course of the illness including complications and precipitating factors. Oral drug therapy has suprisingly often provoked acute pustular eruptions, and these patients have also strikingly often and rapidly developed contact allergy to topical applications. The undesirable effects of long-term systemic corticosteroid therapy have been confirmed in this series, chiefly by severe rebound phenomena, notwithstanding that such treatment has proved the only means of rapidly reversing life-threatening states. The effects of methotrexate and hydroxyurea were at times good but, not uncommonly, mediocre and occasionally even useless. Large doses of antibiotics have also failed to achieve the results described by others. On the contrary, secondary infection with beta-hemolytic streptococci has caused serious problems in several cases. Apart from careful protection from infection and precipitating factors, little can be done to influence the course of generalized pustular psoriasis, but trial with cytostatics is justified during severe bouts, pending the appearance of new lines of therapy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 58523

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  4 in total

1.  Generalized pustular psoriasis triggered by amoxicillin in monozygotic twins with compound heterozygous IL36RN mutations: comment on the article by Navarini et al.

Authors:  Kazumitsu Sugiura; Yukiko Shoda; Masashi Akiyama
Journal:  J Invest Dermatol       Date:  2013-08-20       Impact factor: 8.551

Review 2.  Autoinflammatory pustular neutrophilic diseases.

Authors:  Haley B Naik; Edward W Cowen
Journal:  Dermatol Clin       Date:  2013-06-02       Impact factor: 3.478

Review 3.  Psoriasis. A review of recent advances in treatment.

Authors:  E M Farber; L Nall
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

4.  Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.

Authors:  Kim A Papp; Darryl Toth; Les Rosoph
Journal:  BMC Dermatol       Date:  2006-10-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.